A Phase 2/3 interventional study of Megestrol acetate and Placebo in Dementia, sponsored by Rottapharm Spain. Terminated at 1 site in Spain. Open to participants aged 65 Years to 95 Years. Per ClinicalTrials.gov, last updated 2011-06-08.
Sponsored by Rottapharm Spain · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Dementia with a site in Spain — 27 open to participants now, 37 under way, 9 of them phase 3. Dementia · Spain.
Among the 114 studies in Dementia with a site in Spain, this one is the 83rd largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 2/3, and was the 7th registered.
2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.
Browse Dementia studies →27 of the 114 studies in Dementia with a site in Spain are open now. Recruiting first, the newest first:
Consorci Sanitari de l'Alt Penedès i Garraf · Sites in Spain
Ages 70+
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 18+ · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Institut Investigacio Sanitaria Pere Virgili · Sites in Spain
Ages 60+ · Healthy volunteers
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.
This study: 65 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 31 · Phase 3 34 · Phase 4 2
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 240 across the 95 interventional studies, 327 across the 19 observational. Of the 71 that completed or were terminated, 24 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 114 have an industry lead sponsor. The 10 most frequent:
Rottapharm Spain is the lead sponsor of 9 studies on the registry; none are open to participants now.
Rottapharm Spain has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
7 of the studies in Dementia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT06064890AviadoBio LtdA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) | 2027-04-01 |
| NCT07521722Barcelonabeta Brain Research Center, Pasqual Maragall FoundationDIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community | 2027-04-27 |
| NCT07905872University of Vic - Central University of CataloniaFeasibility of Community Occupational Therapy for Dementia (COT-D) | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 114 studies in Dementia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the efficacy of megestrol acetate in the gain of body weight in patients with primary or mixed Dementia with a weight loss.
In all geriatric patients with dementia it was prove a weight loss independently if they are institutionalized or not.There are some previous studies that indicates the effect of the megestrol acetate in the weight gain of patients with cachexia-anorexia related with neoplasia. It seems that the mechanism of development could be the same between these patients and patients with dementia. It was described an important role of a group of cytokines ( Il-6, leptin, neuropeptide Y, TNFalfa) in the development of this nutritional alteration.
Some previous pilots studies indicates that megestrol acetate has and effect in geriatric and dementia patients with a weight loss of at least 5% in the last 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Megestrol acetate 160 mg b.i.d. during 24 weeks
Drug: Megestrol acetate
1 sachet of powder of placebo b.i.d. during 24 weeks
Drug: Placebo
1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
1 sachet of 160 mg of placebo b.i.d.
To evaluate the change in the body weight
Time frame: 24 weeks
To evaluate the change in the appetite
Time frame: 24 weeks
To evaluate the change in biochemical markers: Il-6, Il-1, leptin, TNFalfa, neuropeptide Y, albumin and prealbumin
Time frame: 24 weeks
Evaluate the change in the nutritional status (Mini-Nutritional Assessment)
Time frame: 24 weeks
To evaluate the change in cognitive state ( Mini-Mental State Examination)
Time frame: 24 weeks
To evaluate the safety of the treatment
Time frame: 24 weeks
The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Megestrol Acetate
Rottapharm Spain